Categories

You can filter the research news archive by selecting one or multiple categories from the following list.






















  Show all news

 

23 November 2018

Lessons about Testosterone Therapy from the Testosterone Trials

Lessons about Testosterone Therapy from the Testosterone Trials

The Testosterone Trials show that testosterone therapy confers significant and clinically meaningful health benefits in older men with low testosterone levels. Even though the Testosterone Trials aimed to recruit men with hypogonadism due to no apparent reason other than age, in fact the majority of enrolled men were obese and more than one third had type 2 diabetes. Obesity, metabolic syndrome and/or type 2 diabetes are stronger risk factors for hypogonadism than aging per se. Consequently, the Testosterone Trials provide compelling evidence that testosterone therapy confers significant benefits in the growing population of men with obesity and/or type 2 diabetes. Furthermore, the Testosterone Trials confirm the safety in this patient population; the placebo group experienced more adverse events than the testosterone group.

An additional notable aspect of the Testosterone Trials is that they refute FDA’s position that testosterone therapy should only be given to men with classical hypogonadism (caused by pituitary injury/tumor, testicular damage or Klinefelter’s syndrome).

15 October 2015

Critical Update of the 2010 Endocrine Society Guidelines for Hypogonadism

Critical Update of the 2010 Endocrine Society Guidelines for Hypogonadism

Critical Update of the 2010 Endocrine Society Clinical Practice Guidelines for Male Hypogonadism: A Systematic Analysis. Seftel AD, Kathrins M, Niederberger C. Mayo Clin Proc. 2015; 90(8): 1104-1115.

In 2010, the Endocrine Society published a Clinical Practice Guideline “Testosterone Therapy in Adult Men With Androgen Deficiency Syndromes”, which addressed important issues regarding the diagnosis and treatment of male hypogonadism.

Since publication of this Guideline, several high-quality trials have been conducted, warranting an update of the 2010 recommendations in several areas, especially that of testosterone therapy in men with the metabolic syndrome, type 2 diabetes, sexual dysfunction, and frailty. In addition, many of the previously stated contraindications to testosterone therapy – including severe lower urinary tract symptoms (LUTS) and untreated obstructive sleep apnea (OSA) - have been reexamined in recent trials.

Here we summarize the results of a systematic analysis of the latest high-quality studies, which call for some important updates of the 2010 Endocrine Society Clinical Practice Guidelines for Male Hypogonadism.


Last updated: 2019
G.MKT.GM.MH.02.2018.0506